# TOMA Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/toma-biosciences

- Industry: Biotechnology
- Headquarters: Holland, US
- Website: www.tomabio.com
- Total disclosed funding: $22M
- Latest round: Series C (Jul 18, 2018)
- Investors on record: 9

## About

TOMA Biosciences, Inc. specializes in biotechnological solutions, focusing on advanced bioinformatics and data analytics to support life sciences research, particularly in pharmaceutical development and personalized medicine.Founded in 2011 and headquartered in Holland, US, TOMA Biosciences, Inc. is dedicated to enhancing research capabilities in the life sciences sector. The company has completed a total of 4 deals, securing a Series C funding round of USD 3.60 mn from investors including Correlation Ventures and Stanford University, representing the total amount raised to date. The founder's specific history is not detailed in the available information.TOMA Biosciences provides innovative bioinformatics and data analytics tools tailored for pharmaceutical development, diagnostics, and personalized medicine applications. Its core offerings are utilized by academic institutions, biotech companies, and healthcare organizations across North America, Europe, and Asia, aiding researchers in analyzing complex biological data effectively.TOMA Biosciences generates revenue primarily through subscriptions to its bioinformatics software platforms and partnerships with research institutions. Their pricing model includes annual subscription fees, allowing access to a suite of tools and services, while also engaging in collaborative projects with biotech firms that provide customized solutions for specific research needs.TOMA Biosciences plans to leverage its recent Series C funding to enhance its product offerings and expand into new geographic markets. The company is focused on launching new tools and analytics solutions aimed at improving research outcomes. Specific target markets and expansion timelines have not been provided, but the recent funding will be instrumental in supporting these growth initiatives.

## Funding rounds

- Series C, Jul 18, 2018, $3.6M — Paladin Capital Group, Prolog Ventures, Correlation Ventures, Keiretsu Forum, Vital Capital Investments, Stanford University, Keiretsu Capital, SAYJ Global Partners
- Series B, Sep 29, 2016, $12M — Paladin Capital Group, Prolog Ventures, Correlation Ventures, Vital Venture Capital
- Series A, Oct 1, 2014, $6M — Paladin Capital Group, Prolog Ventures

## Investors

- Paladin Capital Group (https://capitalatlas.ai/funds/paladin-capital-group) — Series A, Series B, Series C
- Prolog Ventures (https://capitalatlas.ai/funds/prolog-ventures) — Series A, Series B, Series C
- Correlation Ventures (https://capitalatlas.ai/funds/correlation-ventures) — Series B, Series C
- Vital Venture Capital (https://capitalatlas.ai/funds/vital-venture-capital) — Series B
- Keiretsu Forum — Series C
- Vital Capital Investments (https://capitalatlas.ai/funds/vital-capital-investments) — Series C
- Stanford University — Series C
- Keiretsu Capital (https://capitalatlas.ai/funds/keiretsu-capital) — Series C
- SAYJ Global Partners — Series C